Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

Biden to order analysis of pharma supply chain

By Chris Newmarker | February 24, 2021

President Joe Biden

President Joe Biden [Image courtesy of the White House]

President Joe Biden today plans to sign an executive order for a comprehensive review of U.S. supply chains for active pharmaceutical ingredients (APIs) and other products.

The order includes an immediate 100-day review across federal agencies to address vulnerabilities in the supply chains related to APIs and three other key products — critical minerals, semiconductors and advanced packaging, and large-capacity batteries.

There are also plans for a more in-depth one-year review of a broader set of U.S. supply chains, including those supporting defense, public health and biological preparedness, information and communications technology (ICT), the energy sector, transportation and, and agricultural commodities and food production.

A White House fact sheet related to the order notes that more than 70% of API production facilitators supplying the U.S. have moved offshore over the years.

The COVID-19 pandemic quickly caused a painful awareness of how much API production had moved outside the country. Former President Donald Trump in August 2020 signed an executive order meant to encourage the reshoring of pharmaceutical manufacturing to the U.S. Trump’s order included “buy American” provisions for U.S. government agencies’ procurement of essential medicines and reduced regulatory provisions.

The White House fact sheet says Biden’s new order will “complement the ongoing work to secure supply chains needed to combat the COVID-19 pandemic.”

About The Author

Chris Newmarker

Chris Newmarker is the executive editor of WTWH Media life science's news websites and publications including MassDevice, Medical Design & Outsourcing and more. A professional journalist of 18 years, he is a veteran of UBM (now Informa) and The Associated Press whose career has taken him from Ohio to Virginia, New Jersey and, most recently, Minnesota. He’s covered a wide variety of subjects, but his focus over the past decade has been business and technology. He holds bachelor’s degrees in journalism and political science from Ohio State University. Connect with him on LinkedIn or email at cnewmarker@wtwhmedia.com.

Tell Us What You Think! Cancel reply

Related Articles Read More >

Sandoz Logo 2025
Sandoz breaks ground on biosimilar plant in Slovenia
Nymi Logo_2022 (1)
Nymi, Caliber partner on passwordless authentication for pharma manufacturing
Building a resilient pharma supply chain
Antheia_Logo (1)
Pharma ingredient manufacturer Antheia raises $56M Series C
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE